Kavalieris Laimonis, O'Sullivan Paul J, Suttie James M, Pownall Brent K, Gilling Peter J, Chemasle Christophe, Darling David G
Pacific Edge Ltd, Dunedin, New Zealand.
Pacific Edge Diagnostics Ltd, Dunedin, New Zealand.
BMC Urol. 2015 Mar 27;15:23. doi: 10.1186/s12894-015-0018-5.
Hematuria can be symptomatic of urothelial carcinoma (UC) and ruling out patients with benign causes during primary evaluation is challenging. Patients with hematuria undergoing urological work-ups place significant clinical and financial burdens on healthcare systems. Current clinical evaluation involves processes that individually lack the sensitivity for accurate determination of UC. Algorithms and nomograms combining genotypic and phenotypic variables have largely focused on cancer detection and failed to improve performance. This study aimed to develop and validate a model incorporating both genotypic and phenotypic variables with high sensitivity and a high negative predictive value (NPV) combined to triage out patients with hematuria who have a low probability of having UC and may not require urological work-up.
Expression of IGFBP5, HOXA13, MDK, CDK1 and CXCR2 genes in a voided urine sample (genotypic) and age, gender, frequency of macrohematuria and smoking history (phenotypic) data were collected from 587 patients with macrohematuria. Logistic regression was used to develop predictive models for UC. A combined genotypic-phenotypic model (G + P INDEX) was compared with genotypic (G INDEX) and phenotypic (P INDEX) models. Area under receiver operating characteristic curves (AUC) defined the performance of each INDEX: high sensitivity, NPV >0.97 and a high test-negative rate was considered optimal for triaging out patients. The robustness of the G + P INDEX was tested in 40 microhematuria patients without UC.
The G + P INDEX offered a bias-corrected AUC of 0.86 compared with 0.61 and 0.83, for the P and G INDEXs respectively. When the test-negative rate was 0.4, the G + P INDEX (sensitivity = 0.95; NPV = 0.98) offered improved performance compared with the G INDEX (sensitivity = 0.86; NPV = 0.96). 80% of patients with microhematuria who did not have UC were correctly triaged out using the G + P INDEX, therefore not requiring a full urological work-up.
The adoption of G + P INDEX enables a significant change in clinical utility. G + P INDEX can be used to segregate hematuria patients with a low probability of UC with a high degree of confidence in the primary evaluation. Triaging out low-probability patients early significantly reduces the need for expensive and invasive work-ups, thereby lowering diagnosis-related adverse events and costs.
血尿可能是尿路上皮癌(UC)的症状,在初次评估时排除良性病因的患者具有挑战性。接受泌尿外科检查的血尿患者给医疗系统带来了巨大的临床和经济负担。目前的临床评估过程单独来看缺乏准确诊断UC的敏感性。结合基因型和表型变量的算法和列线图主要集中在癌症检测上,未能提高性能。本研究旨在开发并验证一个整合基因型和表型变量的模型,该模型具有高敏感性和高阴性预测值(NPV),用于筛选出患UC可能性低且可能不需要泌尿外科检查的血尿患者。
收集了587例肉眼血尿患者的晨尿样本(基因型)中IGFBP5、HOXA13、MDK、CDK1和CXCR2基因的表达情况,以及年龄、性别、肉眼血尿频率和吸烟史(表型)数据。采用逻辑回归建立UC的预测模型。将联合基因型-表型模型(G + P INDEX)与基因型(G INDEX)和表型(P INDEX)模型进行比较。受试者操作特征曲线下面积(AUC)定义了每个INDEX的性能:高敏感性、NPV>0.97和高检验阴性率被认为是筛选患者的最佳标准。在40例无UC的镜下血尿患者中测试了G + P INDEX的稳健性。
G + P INDEX的偏倚校正AUC为0.86,而P INDEX和G INDEX分别为0.61和0.83。当检验阴性率为0.4时,G + P INDEX(敏感性 = 0.95;NPV = 0.98)比G INDEX(敏感性 = 0.86;NPV = 0.96)性能更佳。使用G + P INDEX正确筛选出了80%无UC的镜下血尿患者,因此这些患者不需要进行全面的泌尿外科检查。
采用G + P INDEX可显著改变临床效用。G + P INDEX可用于在初次评估时高度自信地筛选出患UC可能性低的血尿患者。早期筛选出低概率患者可显著减少昂贵且有创检查的需求,从而降低与诊断相关的不良事件和成本。